Climb Bio to Present at Upcoming Investor Conferences

ELYM 10.31.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-11
Name of Upcoming Event:Guggenheim Securities Healthcare Innovation Conference
Date of Upcoming Event:2024-11-18
Name of Upcoming Event:Stifel 2024 Healthcare Conference
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:36th Annual Piper Sandler Healthcare Conference
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:7th Annual Evercore ISI HealthCONx Conference
Full Press ReleaseSEC FilingsOur ELYM Tweets

About Gravity Analytica

Recent News

  • 01.09.2025 - Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
  • 12.19.2024 - Climb Bio to be Added to the Nasdaq Biotechnology Index
  • 12.03.2024 - December 3, 2024 - December 5, 2024 : 36th Annual Piper Sandler Healthcare Conference

Recent Filings

  • 01.15.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.10.2025 - 8-K Current report

WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.

Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 11-12, 2024

Stifel 2024 Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 18-19, 2024

36thAnnual Piper Sandler Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: December 3-5, 2024

7thAnnual Evercore ISI HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: December 3-5, 2024

The presentations will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website atclimbbio.com.

About Climb Bio, Inc.Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visitclimbbio.com.

InvestorsChris BrinzeyICR Healthcarechris.brinzey@ICRhealthcare.com339-970-2843

MediaJon YuICR Healthcarejon.yu@icrhealthcare.com475-395-5375

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com